Fusion Pharmaceuticals reports Q4 EPS (55c), consensus (56c)

Reports Q4 revenue $100K, consensus $20K. As of December 31, 2022, Fusion held cash, cash equivalents and investments of $186.6M, which Fusion expects will be sufficient to fund operations into 1Q25. CEO John Valliant commented, "We have made significant progress towards our goal of bringing the power of targeted alpha therapies to patients with cancers of high unmet need, while continuing to build on our radiopharmaceutical capabilities, including actinium supply. We have an exciting and diversified pipeline that includes one Phase 2 and three Phase 1 clinical programs, and our first program under the collaboration with AstraZeneca is progressing towards Phase 1 as planned. We believe Fusion is well positioned for further progress in 2023 with preliminary data from the FPI-1434 Phase 1 trial expected in the second quarter of 2023. We are also advancing our newest clinical program, FPI-2265, a small molecule TAT targeting prostate specific membrane antigen for the treatment of metastatic castration-resistant prostate cancer, and are driving towards the opportunity to be first-to-market with an actinium-based PSMA agent to meet a significant and growing need for patients. Our deep pipeline of cancer therapeutic candidates continues to be underpinned by our R&D expertise, and our investments in actinium supply and manufacturing which is a critical element of success in the radiopharmaceutical space. We look forward to providing meaningful updates on our diverse pipeline of TATs in the months ahead."